Loading...

167 posters, 28 videos, 9 topics, 12 sessions, 337 authors, 160 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

ISMICS 2023 Annual Meeting

31 May - 3 June, 2023 | Boston, MA

ISMICS 2023 Annual Meeting banner

PC08

Clinical And Echocardiographic Follow-up In Patiens With Sutureless Perceval Bioprosthesis: Single Center Analysis In 11 Years Experience

Part of Topic

Valve - Surgical Valves

CLINICAL AND ECHOCARDIOGRAPHIC FOLLOW-UP IN PATIENTS WITH SUTURELESS PERCEVAL BIOPROSTHESIS: SINGLE CENTER ANALYSIS IN 11 YEARS EXPERIENCE

Giovanni Concistrè, MD; Giacomo Bianchi, MD, PhD; Rafik Margaryan, MD, PhD; Edoardo Zancanaro, MD; Francesca Chiaramonti, MD, PhD; Enkel Kallushi, MD; Tommaso Gasbarri, MD, PhD; Michele Murzi, MD, PhD; Pierandrea Farneti, MD; Marco Solinas, MD.

 

ABSTRACT

Background:

We describe long-term clinical and echocardiographic follow-up in the largest single center cohort of patients underwent aortic valve replacement (AVR) with sutureless Perceval (CorCym, Italy) bioprosthesis.

Methods:

Between March 2011 and September 2022, 1237 patients underwent AVR with Perceval bioprosthesis implantation. Mean age was 78 ± 4 years and mean EuroSCORE II was 6.9 ± 2.8%. Concomitant procedures were performed in 272 patients (22%).

Results:

Thirty-day mortality was 1.37% (17/1237). 890 of 951 (93.5%) isolated AVR underwent minimally invasive surgery with a ministernotomy (n = 221) or right minithoracotomy (n = 669) approach. Cardiopulmonary bypass and aortic cross-clamp times were 80.6 ± 21.5 and 50.1 ± 10.5 minutes for isolated AVR and 145.8 ± 33.6 and 95.8 ± 20.7 minutes for combined procedures. At mean follow-up of 55.09 ± 6.7 months (range: 1-138.5 months), survival was 95.4% and mean transvalvular pressure gradient was 13.3 ± 4.2 mmHg. LV mass decreased from 153.5 g/m2 to 114.6 g/m2 (p< 0.001) and moderate paravalvular leakage occurred in 3 patients without hemolysis not requiring any treatment. Freedom from reoperation was 97.4%. Nine patients required surgical reintervention and 21 patients transcatheter valve-in-valve procedure for structural prosthesis degeneration at mean of 6.3 years after first operation (range: 2-10 years).

Conclusion:

AVR with Perceval bioprosthesis is associated with good clinical results and excellent hemodynamic performance in our eleven-years experience. Structural degeneration rate of Perceval is comparable with others bioprosthetic aortic valve. Sutureless technology may reduce operative time especially in combined procedures and enable minimally invasive AVR.

@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman"; mso-fareast-language:IT;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Cambria; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS 明朝"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;}div.WordSection1 {page:WordSection1;}

ISMICS 2023 Annual Meeting » banner
Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.